2,864
Views
9
CrossRef citations to date
0
Altmetric
Mental Health

National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States

, , , , , & show all
Pages 792-807 | Received 23 Mar 2022, Accepted 27 May 2022, Published online: 11 Jun 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Pengxiang Li, Carmela Benson, Zhi Geng, Sanghyuk Seo, Charmi Patel & Jalpa A. Doshi. (2023) Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States. Journal of Medical Economics 26:1, pages 525-536.
Read now

Articles from other publishers (8)

Kristin Richards, Michael Johnsrud, Christopher Zacker & Rahul Sasané. (2023) One-Year Medication Treatment Patterns, Healthcare Resource Utilization, and Expenditures for Medicaid Patients with Schizophrenia Starting Oral Atypical Antipsychotic Medication. Administration and Policy in Mental Health and Mental Health Services Research 51:2, pages 207-216.
Crossref
Samuel R. BuntingKristen ChalmersDaniel YohannaRoyce Lee. (2023) Prescription of Long-Acting Injectable Antipsychotic Medications Among Outpatient Mental Health Care Service Providers. Psychiatric Services 74:11, pages 1146-1153.
Crossref
Domicián Máté, Hassan Raza & Ishtiaq Ahmad. (2023) Comparative Analysis of Machine Learning Models for Bankruptcy Prediction in the Context of Pakistani Companies. Risks 11:10, pages 176.
Crossref
Dee Lin, Dominic Pilon, Laura Morrison, Aditi Shah, Marie-Hélène Lafeuille, Patrick Lefebvre & Carmela Benson. (2023) A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia. Drugs - Real World Outcomes 10:3, pages 471-480.
Crossref
Grace Hsin-Min WangMikael SvenssonHui ShaoScott Martin VouriHaesuk Park. (2023) Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia. Journal of Managed Care & Specialty Pharmacy 29:8, pages 884-895.
Crossref
Hilary PhelpsDee LinAlex KeenanAditya RajuDanmeng HuangChih-Yuan ChengCarmela Benson. (2023) Budget impact of introducing once-every-6-months paliperidone palmitate in US health care plans. Journal of Managed Care & Specialty Pharmacy 29:3, pages 303-313.
Crossref
Christoph U. Correll, Carmela Benson, Bruno Emond, Charmi Patel, Marie-Hélène Lafeuille, Dee Lin, Laura Morrison, Isabelle Ghelerter, Patrick Lefebvre & Panagiotis Mavros. (2023) Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophrenia 9:1.
Crossref
Laura MorrisonDee LinCarmela BensonIsabelle GhelerterMaude Vermette-LaformePatrick LefebvreDominic Pilon. (2023) Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate. Journal of Managed Care & Specialty Pharmacy 29:2, pages 161-171.
Crossref